-
COVID-19 vaccines about to be produced in Taizhou!Time of issue : 2020-11-26On the morning of November 23, the news of the official kick-off of the COVID-19 vaccine industrialization base of Jiangsu Rec-Biotechnology Co., Ltd caught the eyes of the public.
-
News | RecBio completed series B round financingTime of issue : 2020-11-11Following the completion of CNY 500 million series A round financing in early 2019, Jiangsu Rec-Biotechnology Co., Ltd (hereinafter referred to as RecBio) recently completed its series B round financing with an amount of over USD 100 million.
-
A Noah's Ark to combat COVID-19Time of issue : 2020-10-27The diagnostic reagents section of China Medical City has collectively risen to prominence in the fight against the COVID-19 pandemic, and made outstanding contributions.
-
Further promote the implementation of IPD system to lay the foundation for a better future of RecBio - Written on the launch of the IPD Phase IITime of issue : 2020-10-27Our company's ongoing development of the Integrated Product Development (IPD) system is a foundation for RecBio's great cause. IPD is an advanced, scientific and mature system of product development models, concepts and methods.
-
Professor Lu Shuihua: Don't let down your guards in this "protracted war" against tuberculosis [Eastern Forum on Tuberculosis - Popular Science].Time of issue : 2020-11-09 -
NEJM: Quadrivalent HPV vaccination can significantly reduce risk of invasive cervical cancer, according to a study of millions of peopleTime of issue : 2020-11-09
- TOP
Contact Us
底部联系方式
Jiangsu Recbio Technology Co., Ltd.
Media Inquiry: media@recbio.cn
Investor Inquiry: ir@recbio.cn
Address: Vaccine Engineering Center, China Medical City, Taizhou
Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd. All rights reserved. 苏ICP备19043567号-1
